{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:14:57Z","timestamp":1790255697902,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human neutrophil antigen-3a (HNA-3a) antibodies contained in donor plasma can result in severe, sometimes fatal transfusion-related acute lung injury (TRALI). Recent developments in TRALI secondary to antibodies to HNA-3a antigen span diagnosis, pathophysiology, treatment, and prevention resulting in improved understanding, potential treatments, and mitigation strategies. First, on the molecular level, characterization of HNA-3 antigen has allowed for genotyping methods that clarify population prevalence. Related work has led to generation of multiple antibody detection assays. These assays aid in determining potential populations at risk and potential mitigation strategies. Second, the development of TRALI requires a hit from the patient and from the product. Anti-HNA-3a is one of the product-derived factors and appears to result in TRALI by binding directly to pulmonary endothelium as well as to neutrophils expressing the corresponding antigen. Finally, potential mitigation strategies include red blood cell product filtration to remove anti-HNA-3a as well as other antibodies.<\/jats:p>","DOI":"10.1182\/blood-2014-05-538181","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T01:35:53Z","timestamp":1404869753000},"page":"1868-1872","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies"],"prefix":"10.1182","volume":"124","author":[{"given":"Emily K.","family":"Storch","sequence":"first","affiliation":[{"name":"New York Blood Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Hillyer","sequence":"additional","affiliation":[{"name":"New York Blood Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-4821","authenticated-orcid":false,"given":"Beth H.","family":"Shaz","sequence":"additional","affiliation":[{"name":"New York Blood Center, New York, NY;"},{"name":"Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111818534517400_B1","unstructured":"US Food and Drug Administration\n          Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/SafetyAvailability\/ReportaProblem\/TransfusionDonationFatalities\/ucm391574.htm. Accessed July 15, 2014"},{"issue":"7","key":"2019111818534517400_B2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood-2011-08-370932","article-title":"Transfusion-related acute lung injury: incidence and risk factors.","volume":"119","author":"Toy","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111818534517400_B3","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00134-007-2875-1","article-title":"A comparison of complication rates based on published haemovigilance data.","volume":"33","author":"Flesland","year":"2007","journal-title":"Intensive Care Med"},{"issue":"1","key":"2019111818534517400_B4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1423-0410.2010.01392.x","article-title":"Antibody-mediated (immune) transfusion-related acute lung injury.","volume":"100","author":"Bux","year":"2011","journal-title":"Vox Sang"},{"issue":"5","key":"2019111818534517400_B5","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2010-04-278135","article-title":"Transfusion-related acute lung injury: from bedside to bench and back.","volume":"117","author":"Shaz","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111818534517400_B6","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.0041-1132.2004.04347.x","article-title":"Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel.","volume":"44","author":"Kleinman","year":"2004","journal-title":"Transfusion"},{"issue":"4","key":"2019111818534517400_B7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1423-0410.2008.01092.x","article-title":"Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors.","volume":"95","author":"Reil","year":"2008","journal-title":"Vox Sang"},{"issue":"1","key":"2019111818534517400_B8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1423-0410.2009.01232.x","article-title":"Frequency and severity of transfusion-related acute lung injury\u2014German haemovigilance data (2006-2007).","volume":"98","author":"Keller-Stanislawski","year":"2010","journal-title":"Vox Sang"},{"key":"2019111818534517400_B9","unstructured":"US Food and Drug Administration\n          Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2007. http:\/\/www.fda.gov\/biologicsbloodvaccines\/safetyavailability\/reportaproblem\/transfusiondonationfatalities\/ucm118316.htm. Accessed July 15, 2014"},{"issue":"3","key":"2019111818534517400_B10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1537-2995.2008.01948.x","article-title":"Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma.","volume":"49","author":"Chapman","year":"2009","journal-title":"Transfusion"},{"issue":"7","key":"2019111818534517400_B11","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1537-2995.2012.03935.x","article-title":"The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy.","volume":"53","author":"Eder","year":"2013","journal-title":"Transfusion"},{"issue":"6","key":"2019111818534517400_B12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/j.1537-2995.2010.02969.x","article-title":"Male-only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study.","volume":"51","author":"Wiersum-Osselton","year":"2011","journal-title":"Transfusion"},{"issue":"3","key":"2019111818534517400_B13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1537-2995.2011.03330.x","article-title":"Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services.","volume":"52","author":"Lin","year":"2012","journal-title":"Transfusion"},{"issue":"1","key":"2019111818534517400_B14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm.2070","article-title":"Characterization of the human neutrophil alloantigen-3a.","volume":"16","author":"Greinacher","year":"2010","journal-title":"Nat Med"},{"issue":"10","key":"2019111818534517400_B15","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2009-11-248336","article-title":"The neutrophil alloantigen HNA-3a (5b) is located on choline transporter-like protein 2 and appears to be encoded by an R>Q154 amino acid substitution.","volume":"115","author":"Curtis","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111818534517400_B16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10930-010-9268-y","article-title":"Isoforms, expression, glycosylation, and tissue distribution of CTL2\/SLC44A2.","volume":"29","author":"Kommareddi","year":"2010","journal-title":"Protein J"},{"issue":"11","key":"2019111818534517400_B17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1161\/ATVBAHA.113.301206","article-title":"Anti-human neutrophil antigen-3a induced transfusion-related acute lung injury in mice by direct disturbance of lung endothelial cells.","volume":"33","author":"Bayat","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"2019111818534517400_B18","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1111\/trf.12160","article-title":"Expression of the CTL2 transcript variants in human peripheral blood cells and human tissues.","volume":"53","author":"Flesch","year":"2013","journal-title":"Transfusion"},{"issue":"5","key":"2019111818534517400_B19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/lary.20136","article-title":"Autoantibodies to recombinant human CTL2 in autoimmune hearing loss.","volume":"119","author":"Kommareddi","year":"2009","journal-title":"Laryngoscope"},{"issue":"5","key":"2019111818534517400_B20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1537-2995.2003.00374.x","article-title":"TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities.","volume":"43","author":"Davoren","year":"2003","journal-title":"Transfusion"},{"issue":"3","key":"2019111818534517400_B21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1537-2995.2006.01148.x","article-title":"The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions.","volume":"47","author":"Fadeyi","year":"2007","journal-title":"Transfusion"},{"issue":"15","key":"2019111818534517400_B22","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1001\/jama.287.15.1968","article-title":"Transfusion-related acute lung injury: report of a clinical look-back investigation.","volume":"287","author":"Kopko","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"2019111818534517400_B23","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2006-05-025106","article-title":"Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model.","volume":"109","author":"Silliman","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111818534517400_B24","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood.V76.7.1438.1438","article-title":"Reproduction of transfusion-related acute lung injury in an ex vivo lung model.","volume":"76","author":"Seeger","year":"1990","journal-title":"Blood"},{"issue":"2","key":"2019111818534517400_B25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.68.2.503","article-title":"Human leukoagglutinating antibody evokes cooperative leukotriene synthesis in pulmonary microvasculature. Model of transfusion-related acute lung injury.","volume":"68","author":"Grimminger","year":"1991","journal-title":"Circ Res"},{"issue":"26","key":"2019111818534517400_B26","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1182\/blood-2012-01-405183","article-title":"Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice.","volume":"119","author":"Thomas","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111818534517400_B27","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1172\/JCI61303","article-title":"Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury.","volume":"122","author":"Caudrillier","year":"2012","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111818534517400_B28","doi-asserted-by":"crossref","first-page":"e32366","DOI":"10.1371\/journal.pone.0032366","article-title":"Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones.","volume":"7","author":"Saffarzadeh","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"2019111818534517400_B29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1189\/jlb.0910538","article-title":"The paradox of the neutrophil\u2019s role in tissue injury.","volume":"89","author":"Segel","year":"2011","journal-title":"J Leukoc Biol"},{"key":"2019111818534517400_B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3662.3662","article-title":"Antibodies specific for human neutrophil antigen 3a (HNA-3a) recognize complex epitopes on choline transporter protein 2 (CTL2): implications for HNA-3a antibody detection.","author":"Bougie","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2019111818534517400_B31","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/blood-2013-10-532424","article-title":"Experimental prestorage filtration removes antibodies and decreases lipid bioactivity accumulation in RBC supernatants mitigating TRALI in vivo.","volume":"123","author":"Silliman","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111818534517400_B32","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1537-2995.2012.03600.x","article-title":"Determination of neutrophil antigen HNA-3a and HNA-3b genotype frequencies in six racial groups by high-throughput 5\u2032 exonuclease assay.","volume":"52","author":"Bowens","year":"2012","journal-title":"Transfusion"},{"issue":"1","key":"2019111818534517400_B33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1537-2995.2010.02751.x","article-title":"Geno- and phenotyping and immunogenicity of HNA-3.","volume":"51","author":"Reil","year":"2011","journal-title":"Transfusion"},{"issue":"3","key":"2019111818534517400_B34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1423-0410.2008.01144.x","article-title":"Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury.","volume":"96","author":"Bierling","year":"2009","journal-title":"Vox Sang"},{"issue":"6","key":"2019111818534517400_B35","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1537-2995.2010.02659.x","article-title":"A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States.","volume":"50","author":"Kleinman","year":"2010","journal-title":"Transfusion"},{"issue":"7","key":"2019111818534517400_B36","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1537-2995.2011.03490.x","article-title":"Detection of HNA-3a and -3b antibodies using transfected cell lines and recombinant proteins.","volume":"52","author":"Wo\u017aniak","year":"2012","journal-title":"Transfusion"},{"issue":"10","key":"2019111818534517400_B37","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1537-2995.2011.03145.x","article-title":"HNA-3a-specific antibodies recognize choline transporter-like protein-2 peptides containing arginine, but not glutamine at position 154.","volume":"51","author":"Curtis","year":"2011","journal-title":"Transfusion"},{"issue":"10","key":"2019111818534517400_B38","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/j.1537-2995.2011.03115.x","article-title":"Epitope mapping of antibodies directed against the human neutrophil alloantigen 3a.","volume":"51","author":"Berthold","year":"2011","journal-title":"Transfusion"},{"issue":"3","key":"2019111818534517400_B39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1537-2995.2011.03303.x","article-title":"Implication of transfected cell lines for the detection of alloantibodies against human neutrophil antigen-3.","volume":"52","author":"Bayat","year":"2012","journal-title":"Transfusion"},{"issue":"5","key":"2019111818534517400_B40","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1537-2995.2011.03411.x","article-title":"Full-length recombinant choline transporter-like protein 2 containing arginine 154 reconstitutes the epitope recognized by HNA-3a antibodies.","volume":"52","author":"Kanack","year":"2012","journal-title":"Transfusion"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/12\/1868\/1379424\/1868.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/12\/1868\/1379424\/1868.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:54:15Z","timestamp":1574103255000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/12\/1868\/33023\/Spotlight-on-pathogenesis-of-TRALI-HNA3a-CTL2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,9,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-05-538181","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]}}}